Scott L. Friedman
Has participated in:
-
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
-
SOX 9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis
-
Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap
-
SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis